Shasun Maintains Hectic Acquisition Pace With Moberg Brands
This article was originally published in PharmAsia News
Strides Shasun, which has been bulking up on new acquisitions to drive long-term growth, has announced the purchase of three over-the-counter brands belonging to Swedish company Moberg Pharma in a deal it says will be immediately accretive to revenues.
You may also be interested in...
Asia Deal Watch: MEI Partners ME-401 With Japan’s Kyowa Hakko Kirin, Following Chinese Deal With BeiGene
About a month after signing a development and commercialization partnership in China for its PI3K delta inhibitor, MEI signs a deal for Japanese rights to the compound with Kyowa Hakko Kirin. Cue and LG Chem partner to develop targeted T-cell therapies for cancer.
For the last few years, Indian generic companies have been making headlines for all the wrong reasons, rapped by the US Food and Drug Administration over problems ranging from fudged test results to poor-quality manufacturing standards. But lately, the firms have been enjoying a run of good regulatory tidings, giving a fillip to their share prices.
Asia’s biggest biotech company, India’s Biocon Ltd, has announced it will conduct what it says is the first-ever clinical trial of a siRNA therapy in India with US partner Quark, is aimed at tackling a rare eye condition.